BiVictriX to present at the Immuno-Oncology Summit Europe 2022

Blog image

Alderley Park, 20 May 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that Oliver Schon, VP ofProduct Development & CMC, will present at the Immuno-Oncology SummitEurope 2022 in London, UK. The conference connects a wide community of pharmaceutical and healthcare professionals and will be held at Hilton London Canary Wharf on23-25 May 2022.

 

The event is comprised of three conference programs that cover therapeutic categories;T-Cell and related Cellular Therapeutics, Bi-specific Antibodies and Therapies targeting the Tumour Microenvironment, while a fourth program covers strategies for Therapeutic Development, including Predictive Biomarkers, Preclinical studies and Translational Studies.

 

The Company’s presentation will be taking place at 16:45pm BST on 25th May as part of the conference’s Bispecific and Multi specific Antibody Therapeutics section and will discuss the development of a bispecific antibody drug conjugate (ADC) for the treatment of acute myeloid leukaemia (AML).

The presentation is available on BiVictriX’s website here

newsletter

Contact BivictriX

Please submit the form below and we shall be in touch
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AntibodyPatient Image